Trial Profile
A Single Centre, Two-part, Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of Ascending Oral Doses of MMV390048 and Its Antimalarial Activity Against Plasmodium Falciparum in Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Apr 2020
Price :
$35
*
At a glance
- Drugs MMV 390048 (Primary)
- Indications Falciparum malaria
- Focus Therapeutic Use
- 02 Apr 2020 Results characterizing the safety, pharmacokinetics and antimalarial activity of a tablet formulation of MMV390048 published in the Clinical Infectious Diseases
- 07 Feb 2017 Status changed from active, no longer recruiting to completed.
- 16 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Jan 2017.